Pepinemab

Phase 2

Vaccinex, Inc. (VCNX)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

10 competitors in Alzheimer Disease

SAVASimufilam

Phase 3

SNYxaliproden (SR57746A)

Drug Information

Target Indication

Alzheimer Disease

Clinical Trial

NCT04381468

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

VCNX

Vaccinex, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)Phase 3

Human Papillomavirus (HPV) Infection

11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)Phase 3

HPV InfectioN

Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)Phase 3

Norovirus Infections

VX15/2503Phase 2

Huntington's Disease

Avelumab and PepinemabPhase 2

Metastatic Pancreatic Adenocarcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts